Cargando empresa
Just reported
From Amgen's results release of 3 de noviembre de 2026; its quarterly report has since been filed.
Actual
10,37B US$
+8,5 % y/y
+3,1 % q/q
Guided
—
No guide given
Actual
7,08 US$
+19 % y/y
+62 % q/q
Guided
—
No guide given
Actual
3,71B US$
+47 % y/y
+5,6 % q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Los porcentajes de ingresos son estimaciones para year ended 2025-12-31, high confidence, no cifras de un informe oficial.
Repatha
An injectable medicine that lowers LDL cholesterol and is used to reduce the chance of major heart and blood-vessel events in certain adults.
Prolia
A medicine for osteoporosis that helps reduce fracture risk in certain people, including postmenopausal women and men at high risk of fracture.
Otezla
An oral medicine used for plaque psoriasis, psoriatic arthritis and certain mouth ulcers.
ENBREL
A medicine used for rheumatoid arthritis, plaque psoriasis and psoriatic arthritis.
TEZSPIRE
An antibody medicine used as an add-on treatment for severe uncontrolled asthma and, in approved markets, chronic sinus inflammation with nasal polyps.
IMDELLTRA
A cancer medicine for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy.
Estados financieros completos →
Amgen researches, develops and manufactures medicines, including biologic medicines made using living cells and small-molecule drugs. It sells treatments for conditions including heart disease, cancer, osteoporosis, asthma and autoimmune diseases. It also sells biosimilar medicines, which are highly similar versions of existing biologic medicines.
Construido a partir de los propios informes de Amgen Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
The themes Amgen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,36T US$A+
JNJJohnson & Johnson688,6B US$A+
MRKMerck & Co., Inc.364,3B US$A
NVSNovartis AG306,3B US$A
GILDGilead Sciences, Inc.208,4B US$ARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now AAmgen discovers, makes and sells prescription medicines for serious diseases, along with biosimilar medicines.
Previsión de la empresa: ingresos de de 38,9B US$ a 39,7B US$ para Año fiscal 2026 — un 6,9 % más que un año antes
Grade A+
La franja bajo el precio muestra la calificación en cada fecha, calculada solo con los informes ya públicos en ese momento.
Mostrando 2 de 41 trimestres del historial de calificaciones de Amgen Inc.. Los otros 39 llegan hasta octubre de 2016.
